EPS for Biomerica, Inc. (BMRA) Expected At $-0.03

September 17, 2017 - By Nellie Frank

 EPS for Biomerica, Inc. (BMRA) Expected At $ 0.03

Analysts await Biomerica, Inc. (NASDAQ:BMRA) to report earnings on October, 16. They expect $-0.03 EPS, down 200.00 % or $0.02 from last year’s $-0.01 per share. After $-0.04 actual EPS reported by Biomerica, Inc. for the previous quarter, Wall Street now forecasts -25.00 % EPS growth. The stock decreased 1.07% or $0.03 on September 15, reaching $2.78. About 13,027 shares traded or 26.93% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since September 17, 2016 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc. is a biomedical company, which develops, makes and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company has market cap of $23.66 million. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care . It currently has negative earnings. The Firm operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Quotes.Wsj.com which released: “Biomerica Inc.” on February 27, 2011, also Globenewswire.com with their article: “Biomerica Announces Point of Care Product Distribution Agreement with a …” published on August 16, 2017, Globenewswire.com published: “Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test” on September 12, 2017. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Marketwatch.com and their article: “2.78” published on April 19, 2011 as well as Globenewswire.com‘s news article titled: “Biomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for …” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.